Performance of HPV DNA testing in the follow-up after treatment of high-grade cervical lesions, adenocarcinoma in situ (AIS) and microinvasive carcinoma

ecancermedicalscience

Volumn 9, Issue , 2015, Pages

  Costa, Silvano ^a,b   Venturoli, Simona ^a   Origoni, Massimo ^c   Preti, Mario ^d   Mariani, Luciano ^e   Cristoforoni, Paolo ^f   Sandri, Maria Teresa ^d  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b MF Toniolo Hospital   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

Author keywords

Adenocarcinioma in situ; CIN recurrence; CIN2+ lesion; Follow up; Genotyping; HPV testing; Microinvasive squamous carcinoma

Indexed keywords

VIRUS DNA;

ADENOCARCINOMA IN SITU; CANCER GROWTH; CANCER RECURRENCE; COLPOSCOPY; DIAGNOSTIC TEST ACCURACY STUDY; DNA DETERMINATION; EARLY DIAGNOSIS; FOLLOW UP; GENOTYPE; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; INVASIVE CARCINOMA; OBSERVATIONAL STUDY; PAPANICOLAOU TEST; PREDICTIVE VALUE; REPRODUCIBILITY; REVIEW; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SQUAMOUS INTRAEPITHELIAL LESION OF THE CERVIX; SYSTEMATIC REVIEW; UTERINE CERVIX CARCINOMA; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CONIZATION; VIRAL CLEARANCE; WART VIRUS;

EID: 84932599130     PISSN: None     EISSN: 17546605     Source Type: Journal    
DOI: 10.3332/ecancer.2015.528     Document Type: Review

References (31)

1. Paraskevaidis E et al (2001) The role of HPV DNA testing in the follow-up period after treatment for CIN: a systematic review of the literature Cancer Treat Rev 30(2) 205-211 DOI: 10.1016/j.ctrv.2003.07.008
2. Arbyn M et al (2006) Chapter 9: Clinical applications of HPV testing: A summary of meta-analyses Vaccine 24(Suppl 3) S3/78-89 DOI: 10.1016/j.vaccine.2006.05.117
3. Sarian LO et al (2004) Factors associated with HPV persistence after treat ment for high-grade cervical intra-epithelial neoplasia with large loop excision of the transformation zone (LLETZ) J Clin Virol 31(4) 270-4 DOI: 10.1016/j.jcv.2004.05.012 PMID: 15494268
4. Zielinski GD et al (2004) HPV testing and monitoring of women after treatment of CIN 3: review of the literature and metaanalysis Obstet Gynecol Surv 59(7) 543-53 DOI: 10.1097/00006254-200407000-00024 PMID: 15199273
5. Melnikow J et al (2009) Cervical intraepithelial neoplasia outcomes after treat ment: long-term follow-up from the British Columbia cohort study J Natl Cancer Inst 101 721-8 DOI: 10.1093/jnci/djp089 PMID: 19436026 PMCID: 2684554
6. Costa S et al (2002) Disease persistence in patients with cervical intraepithelial neoplasia undergoing electrosurgical conization Gynecol Oncol 85(1) 119-24 DOI: 10.1006/gyno.2001.6579 PMID: 11925130
7. Kocken M et al (2011) Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study Lancet Oncol 12(5) 441-50 DOI: 10.1016/S1470-2045(11)70078-X PMID: 21530398
8. Soutter WP, Sasieni P and Paraskevaidis E (2006) Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia Int J Cancer 118(8) 2048-55 DOI: 10.1002/ijc.21604
9. J Jordan P et al (2009) European guidelines for clinical management of abnormal cervical cytology, Part 2 Cytopathology 20(1) 5-16 DOI: 10.1111/j.1365-2303.2008.00636.x
10. Costa S et al (2003) Factors predicting human papillomavirus clearance in cervical intraepithelial neoplasia lesions treated by conization Gynecol Oncol 90(2) 358-65 DOI: 10.1016/S0090-8258(03)00268-3 PMID: 12893200
11. Massad LS et al (2012) ASCCP Consensus Guidelines Conference 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors Obstet Gynecol 121(4) 829-46
12. Venturoli S et al (2008) Correlation of high-risk human papillomavirus genotypes persistence and risk of residual or recurrent cervical disease after surgical treatment J Med Virol 80(8) 1434-40 DOI: 10.1002/jmv.21198 PMID: 18551620
13. Origoni M et al (2012) HPV-DNA testing for cervical cancer precursors: from evidence to clinical practice Ecancermedicalscience 6 258 PMID: 22778786 PMCID: 3388143
14. Soderlund-Strand A, Kjellberg L and Dillner J (2014) Human Papillomavirus Type-Specific Persistence and Recurrence After Treatment for Cervical Dysplasia J Med Virol 86(4) 634-64 DOI: 10.1002/jmv.23806
15. Rositch AF et al (2014) The incidence of human papillomavirus infection following treatment for cervical neoplasia: a systematic review Gynecol Oncol 132(3) 767-79 DOI: 10.1016/j.ygyno.2013.12.040 PMID: 24412508
16. M Cricca et al (2007) Viral DNA load, physical status and E2/E6 ratio as markers to grade HPV16 positive women for high-grade cervical lesions Gynecol Oncol 106(3) 549-57 DOI: 10.1016/j.ygyno.2007.05.004 PMID: 17568661
17. Frega A et al (2014) Assessment of HPV-mRNA test to predict recurrent disease in patients previously treated for CIN 2/3 J Clin Virol 60(1) 39-43 DOI: 10.1016/j.jcv.2014.01.017 PMID: 24602516
18. EA Burger et al (2011) HPV mRNA tests for the detection of cervical intraepithelial neoplasia: a systematic review Gynecol Oncol 120(3) 430-8 DOI: 10.1016/j.ygyno.2010.11.013
19. Arbyn M et al (2005) Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence Gynecol Oncol 99(3 Suppl 1) 7-11 DOI: 10.1016/j.ygyno.2005.07.033
20. Smith HO et al (2000) The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the US. A 24-year population based study Gynecol Oncol 78 97-105 DOI: 10.1006/gyno.2000.5826 PMID: 10926787
21. Bryson P et al (2004) Is electrosurgical loop excision with negative margins sufficient treatment for cervical ACIS? Gynecol Oncol 93(2) 465-8 DOI: 10.1016/j.ygyno.2004.01.028 PMID: 15099963
22. American College of Obstetricians and Gynecologists (2008) ACOG Practice Bulletin No. 99 (2008): management of abnormal cervical cytology and histology Obstet Gynecol 112(6) 1419-44 DOI: 10.1097/AOG.0b013e318192497c PMID: 19037054
23. Cohn DE et al (2005) Invasive cervical adenocarcinoma immediately following a cone biopsy for adenocarcinoma in situ with negative margins Gynecol Oncol 98(1) 158-60 DOI: 10.1016/j.ygyno.2005.04.013 PMID: 15913738
24. Costa S et al (2007) Human papillomavirus (HPV) test and PAP smear as predictors of outcome in conser vatively treated adenocarcinoma in situ (AIS) of the uterine cervix Gynecol Oncol 106(1) 170-6 DOI: 10.1016/j.ygyno.2007.03.016 PMID: 17481701
25. Costa S et al (2012) Factors predicting the outcome of conservatively treated adenocarcinoma in situ of the uterine cervix: an analysis of 166 cases Gynecol Oncol 124(3) 490-5 DOI: 10.1016/j.ygyno.2011.11.039
26. Kolstad P (1989) Follow up study of 232 patients with stage 1A1 and 411 patients with stage 1A2 squamous cell carcinoma of the cervix Gynaecol Oncol 33(3) 265-72 DOI: 10.1016/0090-8258(89)90510-6
27. Costa S et al (2009) Outcome of Conservatively Treated Microinvasive Squamous Cell Carcinoma of the Uterine Cervix During a 10-Year Follow-up Int J Gynecol Cancer 19(1) 33-38 DOI: 10.1111/IGC.0b013e318197f53b PMID: 19258938
28. Tseng C, Liang C and Lin C (1999) A study of diagnostic failure of loop conization in microinvasive carcinoma of the cervix Gynecol Oncol 73(1) 91-5 DOI: 10.1006/gyno.1998.5295 PMID: 10094886
29. Orlandi C et al (1995) Presurgical assessment and therapy of microinvasive carcinoma of the cervix Gynecol Oncol 59(2) 255-60 DOI: 10.1006/gyno.1995.0018 PMID: 7590483
30. Cairns M et al (2010) High-risk HPV genotyping in the follow-up of women treated conservatively for microinvasive cervical cancer Int J Gynecol Cancer 20(1) 154-7 DOI: 10.1111/IGC.0b013e3181c3a6b6 PMID: 20130517
31. Korolenkova LI (2011) Value of HPV (hybrid capture 2) testing for assessing the effectiveness of conservative surgical treatment in CIN2-3/carcinoma in situ and microinvasive cervical cancer Vopr Onkol 57(3) 322-6 PMID: 21882603